MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.gaceta.2009.05.007

Медицинская библиотека · Gaceta sanitaria · 2009

[Economic evaluation and budget impact analysis of the Endeavor drug-eluting stent in Spain].

Moreu José, Cequier Angel, Brosa Max, Rodríguez José M, Crespo Carlos, Hernández José M, Vázquez Nicolás, Fernández Felipe, Ruiz-Nodar Juan M, Brasseur Pascal

Сравнительное исследованиеАннотация на английскомСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

Endeavor is a drug-eluting stent (DES) with superior results to the bare metal stent (BMS) and similar efficacy to other DES in terms of revascularization. The aim of this study was to assess the costs and benefits of Endeavor, other DES, BMS and coronary artery bypass grafts (CABG) in Spain.

METHODS

A Markov model with a 5-year time was used to reflect the management of patients with de novo coronary artery lesions in Spain. Model probabilities were derived from systematic reviews and randomized controlled trials of Endeavor. Health resources and costs were obtained from local data and were validated by experts. Effectiveness was measured as the number of revascularizations avoided, the major adverse coronary events (MACE) avoided and the quality adjusted life-years (QALYs) gained.

RESULTS

Endeavor had higher total costs than the BMS. The cost per revascularization avoided with Endeavor was 6,851 euro (at 1 year) and 10,831 euro (at 5 years). In terms of cost per MACE avoided with Endeavor, the results were 7,003 euro and 11,322 euro, respectively, and in terms of costs of QALY gained were 132,877 euro, 34,229 euro and 10,505 euro at 1, 2, and 5 years, respectively. The budget impact of the progressive introduction of Endeavor would be practically null, representing 0.4% of the total cost of percutaneous coronary interventions at 5 years.

CONCLUSIONS

The use of the Endeavor stent compared with BMS and CABG represents efficient resource use in patients with coronary artery disease, with cost-effectiveness results below the threshold of efficiency defined in Spain.

Для цитирования: Moreu José, Cequier Angel, Brosa Max, Rodríguez José M, Crespo Carlos, Hernández José M, Vázquez Nicolás, Fernández Felipe, Ruiz-Nodar Juan M, Brasseur Pascal. [Economic evaluation and budget impact analysis of the Endeavor drug-eluting stent in Spain].. Gaceta sanitaria. 2009. DOI: 10.1016/j.gaceta.2009.05.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.